Astec Lifesciences Share Price

Agrochemicals company Astec Lifesciences announced Q4FY26 & FY26 results Q4FY26 Standalone Financial Highlights: Revenue from Operations: Rs 15,862.27 lakh, representing a QoQ increase of 27.18% compared to Rs 12,472.03 lakh and a YoY increase of 32.71% compared to Rs 11,952.70 लाख. कुल इनकम: ₹ 16,123.68 lakh, representing a QoQ increase of 28.46% and a YoY increase of 34.02%. Net Loss: Rs 778.18 lakh, representing a reduction in loss by 50.49% QoQ (from Rs 1,571.97 lakh) and a reduction in loss by 51.66% YoY (from Rs 1,609.85 लाख). Earnings Per Share (Basic): Loss of Rs 3.49 compared to a loss of Rs 7.06 in the previous quarter and a loss of Rs 8.21 in the same quarter last year. Q4FY26 Consolidated Financial Highlights: Revenue from Operations: Rs 15,862.26 lakh, representing a QoQ increase of 27.18% and a YoY increase of 32.71% compared to Rs 11,952.70 Q4FY25 में लाख. कुल इनकम: ₹ 16,125.62 lakh, representing a QoQ increase of 28.46% and a YoY increase of 34.03%. Net Loss: Rs 774.70 lakh, representing a reduction in loss by 50.61% QoQ (from Rs 1,568.53 lakh) and a reduction in loss by 51.82% YoY (from Rs 1,607.90 लाख). Earnings Per Share (Basic): Loss of Rs 3.48 compared to a loss of Rs 7.04 in the previous quarter and a loss of Rs 8.20 in the same quarter last year. FY26 Standalone Financial Highlights: Revenue from Operations: Rs 44,814.56 lakh for FY26, representing a YoY increase of 17.53% compared to Rs 38,130.35 एफवाई25 में लाख. कुल इनकम: ₹ 45,313.43 lakh, representing a YoY increase of 17.13% from Rs 38,686.16 लाख. Net Loss: Rs 8,100.88 lakh for FY26, representing a 39.91% reduction in loss compared to a loss of Rs 13,480.82 एफवाई25 में लाख. Cash Flow from Operating Activities: Net cash used in operating activities stood at Rs (8,059.10) lakh for FY26, compared to Rs (839.00) एफवाई25 में लाख. Earnings Per Share (Basic): Loss of Rs 37.83 compared to a loss of Rs 68.74 in the previous year. FY26 Consolidated Financial Highlights: Revenue from Operations: Rs 44,814.56 lakh for FY26, representing a YoY increase of 17.53% compared to Rs 38,130.35 एफवाई25 में लाख. Total Income: Rs 45,321.65 lakh, representing a YoY increase of 17.13% from Rs 38,693.22 लाख. Net Loss: Rs 8,087.62 lakh for FY26, representing a 39.96% reduction in loss compared to a loss of Rs 13,471.17 एफवाई25 में लाख. Earnings Per Share (Basic): Loss of Rs 37.79 compared to a loss of Rs 68.71 in FY25. Net Worth: Rs 39,091.79 lakh as of March 31, 2026, representing a YoY increase of 66.53% compared to Rs 23,474.52 lakh as of March 31, 2025. Business Highlights: Single Business Segment: The Group operates in only one reportable segment: "Agro-chemicals". Capital Raising: The company successfully completed a Rights Issue in July 2025, allotting 26,69,951 fully paid-up equity shares at Rs 890 per share, raising approximately Rs 23,762.56 लाख. Exceptional Item: The results for FY26 include an exceptional charge of Rs 209.43 lakh (Standalone and Consolidated) towards incremental employee benefit obligations (gratuity and compensated absences) following the notification of new Labour Codes. Credit Rating: The company is rated "CARE AA- Stable" for long-term bank facilities and "CARE A1+" for short-term bank facilities. Vishal Sharma, Chairperson, Astec LifeSciences, said: In Q4FY26, Astec delivered strong revenue growth of 34% YoY primarily on the back of improved volumes in both the categories, i.e. Enterprise and Contract Manufacturing segment. Revenue increased sequentially as well by 29% over Q3FY26, primarily driven by Enterprise Volumes. Improved volumes in the Enterprise and CDMO segments drove a significant margin expansion, leading to an increase in EBITDA to Rs 11.8 crore in Q4FY26 from Rs 6.3 crore in Q4FY25, an 87% YoY growth. परिणाम PDF

• ट्रेंडलाइन
• 1 महीने 3 सप्ताह पहले

Agrochemicals company Astec Lifesciences announced Q2FY26 results The Company reported consolidated total income of Rs 74.8 crore in Q2FY26 as compared to Rs 100.5 crore in Q2FY25. The Company reported consolidated EBITDA loss of Rs 5.6 crore in Q2FY26 as compared to EBITDA loss of Rs 17.7 crore in Q2FY25. N B Godrej, Chairman, Astec LifeSciences, said: Astec recorded year-on-year and sequential improvement in its performance in Q2FY26. The EBITDA loss narrowed to Rs 5.6 crore, reflecting a positive trend compared to previous quarters. This improvement was largely driven by higher volumes and better gross margins in the Enterprise business. Conversely, the contract manufacturing segment experienced a YoY revenue decline, as the cautious stance adopted by the contract manufacturing customers impacted performance during the quarter. परिणाम PDF

• ट्रेंडलाइन
• 7 महीने 2 सप्ताह पहले

Agrochemicals company Astec Lifesciences announced Q1FY26 results The Company reported consolidated total income of Rs 91.6 crore in Q1FY26 as compared to Rs 70.3 crore in Q1FY25. The consolidated total income in Q1FY 26 increased by 30.3% over Q1 FY25. The Company reported consolidated EBITDA loss of Rs 10.5 crore in Q1FY26 as compared to loss of Rs 45.3 crore in the same period last year. Commenting on the performance, N B Godrej, Chairman, Astec LifeSciences, said: Astec reported improvement in performance on a year on year basis on the back of improvement in volumes & contribution in its enterprise business. Revenue in enterprise & CDMO businesses increased year on year by 68.2% & 85.7% respectively. This also resulted in reduction of EBITDA losses as compared to Q1 FY25, which also had an impact of write down of Inventories of Rs 18.5 crore. परिणाम PDF

• ट्रेंडलाइन
• 10 महीने 2 सप्ताह पहले